Year |
Citation |
Score |
2023 |
Terron HM, Parikh SJ, Abdul-Hay SO, Sahara T, Kang D, Dickson DW, Saftig P, LaFerla FM, Lane S, Leissring MA. Prominent tauopathy and intracellular β-amyloid accumulation triggered by genetic deletion of cathepsin D: Implications for Alzheimer disease pathogenesis. Research Square. PMID 37961253 DOI: 10.21203/rs.3.rs-3464352/v1 |
0.507 |
|
2023 |
Terron HM, Maranan DS, Burgard LA, LaFerla FM, Lane S, Leissring MA. A Dual-Function "TRE-Lox" System for Genetic Deletion or Reversible, Titratable, and Near-Complete Downregulation of Cathepsin D. International Journal of Molecular Sciences. 24. PMID 37047718 DOI: 10.3390/ijms24076745 |
0.429 |
|
2020 |
Suire CN, Abdul-Hay SO, Sahara T, Kang D, Brizuela MK, Saftig P, Dickson DW, Rosenberry TL, Leissring MA. Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40. Alzheimer's Research & Therapy. 12: 80. PMID 32631408 DOI: 10.1186/S13195-020-00649-8 |
0.369 |
|
2019 |
Fernandez-Diaz CM, Merino B, Lopez-Acosta JF, Cidad P, de la Fuente MA, Lobaton CD, Moreno A, Leissring MA, Perdomo G, Cozar-Castellano I. Pancreatic beta-cell-specific deletion of insulin-degrading enzyme leads to dysregulated insulin secretion and beta-cell functional immaturity. American Journal of Physiology. Endocrinology and Metabolism. PMID 31479304 DOI: 10.1152/Ajpendo.00040.2019 |
0.311 |
|
2016 |
Hogan MF, Meier DT, Zraika S, Templin AT, Mellati M, Hull RL, Leissring MA, Kahn SE. Inhibition of Insulin-Degrading Enzyme Does Not Increase Islet Amyloid Deposition In Vitro. Endocrinology. en20161410. PMID 27404391 DOI: 10.1210/En.2016-1410 |
0.346 |
|
2015 |
Li H, Zhu H, Wallack M, Mwamburi M, Abdul-Hay SO, Leissring MA, Qiu WQ. Age and Its Association with Low Insulin and High Amyloid-β Peptides in Blood. Journal of Alzheimer's Disease : Jad. PMID 26444783 DOI: 10.3233/Jad-150428 |
0.344 |
|
2014 |
Leissring MA. Aβ degradation-the inside story. Frontiers in Aging Neuroscience. 6: 229. PMID 25206334 DOI: 10.3389/Fnagi.2014.00229 |
0.343 |
|
2013 |
Leissring MA, Turner AJ. Regulation of distinct pools of amyloid β-protein by multiple cellular proteases. Alzheimer's Research & Therapy. 5: 37. PMID 23953275 DOI: 10.1186/Alzrt194 |
0.396 |
|
2013 |
Abdul-Hay SO, Lane AL, Caulfield TR, Claussin C, Bertrand J, Masson A, Choudhry S, Fauq AH, Maharvi GM, Leissring MA. Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity. Journal of Medicinal Chemistry. 56: 2246-55. PMID 23437776 DOI: 10.1021/Jm301280P |
0.307 |
|
2012 |
Abdul-Hay SO, Sahara T, McBride M, Kang D, Leissring MA. Identification of BACE2 as an avid ß-amyloid-degrading protease. Molecular Neurodegeneration. 7: 46. PMID 22986058 DOI: 10.1186/1750-1326-7-46 |
0.365 |
|
2012 |
Liu Z, Zhu H, Fang GG, Walsh K, Mwamburi M, Wolozin B, Abdul-Hay SO, Ikezu T, Leissring MA, Qiu WQ. Characterization of insulin degrading enzyme and other amyloid-β degrading proteases in human serum: a role in Alzheimer's disease? Journal of Alzheimer's Disease : Jad. 29: 329-40. PMID 22232014 DOI: 10.3233/Jad-2011-111472 |
0.358 |
|
2010 |
Leissring MA, Malito E, Hedouin S, Reinstatler L, Sahara T, Abdul-Hay SO, Choudhry S, Maharvi GM, Fauq AH, Huzarska M, May PS, Choi S, Logan TP, Turk BE, Cantley LC, et al. Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. Plos One. 5: e10504. PMID 20498699 DOI: 10.1371/Journal.Pone.0010504 |
0.301 |
|
2010 |
DelleDonne A, Miles RJ, Dickson DW, Abdul-Hay SO, Ertekin-Taner N, Leissring MA. P1-292: Correlation between insulin-degrading enzyme levels and neuropathology in control versus Alzheimer brains with and without cerebral amyloid angiopathy Alzheimer's & Dementia. 6: S258-S258. DOI: 10.1016/J.Jalz.2010.05.844 |
0.325 |
|
2009 |
Cabrol C, Huzarska MA, Dinolfo C, Rodriguez MC, Reinstatler L, Ni J, Yeh LA, Cuny GD, Stein RL, Selkoe DJ, Leissring MA. Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening. Plos One. 4: e5274. PMID 19384407 DOI: 10.1371/Journal.Pone.0005274 |
0.318 |
|
2009 |
Zhao J, Li L, Leissring MA. Insulin-degrading enzyme is exported via an unconventional protein secretion pathway. Molecular Neurodegeneration. 4: 4. PMID 19144176 DOI: 10.1186/1750-1326-4-4 |
0.4 |
|
2009 |
Leissring MA, Reinstatler L, Sahara T, Sevlever D, Roman R, Ji Z, Li L, Lu Q, Säftig P, Levites Y, Golde TE, Burgess J, Ertekin-Taner N, Eckman EA. O4-03-07: Cathepsin D knockout mice harbor large and highly selective increases in cerebral Aß42 and tau: Implications for Alzheimer's disease pathogenesis Alzheimer's & Dementia. 5: P155-P156. DOI: 10.1016/J.Jalz.2009.05.537 |
0.315 |
|
2008 |
Leissring MA. The AbetaCs of Abeta-cleaving proteases. The Journal of Biological Chemistry. 283: 29645-9. PMID 18723506 DOI: 10.1074/Jbc.R800022200 |
0.385 |
|
2008 |
Neant-Fery M, Garcia-Ordoñez RD, Logan TP, Selkoe DJ, Li L, Reinstatler L, Leissring MA. Molecular basis for the thiol sensitivity of insulin-degrading enzyme. Proceedings of the National Academy of Sciences of the United States of America. 105: 9582-7. PMID 18621727 DOI: 10.1073/Pnas.0801261105 |
0.345 |
|
2008 |
Betts V, Leissring MA, Dolios G, Wang R, Selkoe DJ, Walsh DM. Aggregation and catabolism of disease-associated intra-Abeta mutations: reduced proteolysis of AbetaA21G by neprilysin. Neurobiology of Disease. 31: 442-50. PMID 18602473 DOI: 10.1016/J.Nbd.2008.06.001 |
0.378 |
|
2007 |
Im H, Manolopoulou M, Malito E, Shen Y, Zhao J, Neant-Fery M, Sun CY, Meredith SC, Sisodia SS, Leissring MA, Tang WJ. Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE. The Journal of Biological Chemistry. 282: 25453-63. PMID 17613531 DOI: 10.1074/Jbc.M701590200 |
0.325 |
|
2007 |
Kim M, Hersh LB, Leissring MA, Ingelsson M, Matsui T, Farris W, Lu A, Hyman BT, Selkoe DJ, Bertram L, Tanzi RE. Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families. The Journal of Biological Chemistry. 282: 7825-32. PMID 17244626 DOI: 10.1074/Jbc.M609168200 |
0.36 |
|
2006 |
Betts V, Leissring MA, Selkoe DJ, Walsh DM. P1-391: Monomeric Aβ peptides bearing the Flemish A21G mutation are less readily degraded by neprilysin than wild type Aβ Alzheimer's & Dementia. 2: S212-S213. DOI: 10.1016/J.Jalz.2006.05.769 |
0.335 |
|
2005 |
Farris W, Leissring MA, Hemming ML, Chang AY, Selkoe DJ. Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein. Biochemistry. 44: 6513-25. PMID 15850385 DOI: 10.1021/Bi0476578 |
0.395 |
|
2004 |
Bishop G, Coleman P, Crutcher K, David D, Kinoshita J, LaFerla F, Leissring M, Shepherd J, Therianos S, Wang R, Wilson A, Zhu M. Live discussion: how the other half lives - or the what, how, and where, of the AbetaPP intracellular domain. Journal of Alzheimer's Disease : Jad. 6: 193-9. PMID 15171221 DOI: 10.3233/Jad-2004-6212 |
0.406 |
|
2004 |
Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, Tanzi RE, Selkoe DJ. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. The American Journal of Pathology. 164: 1425-34. PMID 15039230 DOI: 10.1016/S0002-9440(10)63229-4 |
0.301 |
|
2004 |
Akbari Y, Dagher N, Murphy MP, Kozak JA, Hitt B, Oddo S, Tseng B, Golde TE, Cahalan M, Leissring MA, M. LaFerla F. P1-206 Capacitative and non-capacitative Ca2+ entry modulate Aβ levels Neurobiology of Aging. 25: S154-S155. DOI: 10.1016/S0197-4580(04)80519-0 |
0.683 |
|
2002 |
Sugarman MC, Yamasaki TR, Oddo S, Echegoyen JC, Murphy MP, Golde TE, Jannatipour M, Leissring MA, LaFerla FM. Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proceedings of the National Academy of Sciences of the United States of America. 99: 6334-9. PMID 11972038 DOI: 10.1073/Pnas.082545599 |
0.692 |
|
2002 |
Leissring MA, Murphy MP, Mead TR, Akbari Y, Sugarman MC, Jannatipour M, Anliker B, Müller U, Saftig P, De Strooper B, Wolfe MS, Golde TE, LaFerla FM. A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. Proceedings of the National Academy of Sciences of the United States of America. 99: 4697-702. PMID 11917117 DOI: 10.1073/Pnas.072033799 |
0.731 |
|
2001 |
Leissring MA, LaFerla FM, Callamaras N, Parker I. Subcellular mechanisms of presenilin-mediated enhancement of calcium signaling. Neurobiology of Disease. 8: 469-78. PMID 11442355 DOI: 10.1006/Nbdi.2001.0382 |
0.594 |
|
2001 |
Marchant JS, Stutzmann GE, Leissring MA, LaFerla FM, Parker I. Multiphoton-evoked color change of DsRed as an optical highlighter for cellular and subcellular labeling. Nature Biotechnology. 19: 645-9. PMID 11433276 DOI: 10.1038/90249 |
0.463 |
|
2000 |
LaFerla FM, Sugarman MC, Lane TE, Leissring MA. Regional hypomyelination and dysplasia in transgenic mice with astrocyte-directed expression of interferon-gamma. Journal of Molecular Neuroscience : Mn. 15: 45-59. PMID 11211236 DOI: 10.1385/Jmn:15:1:45 |
0.501 |
|
2000 |
Leissring MA, Yamasaki TR, Wasco W, Buxbaum JD, Parker I, LaFerla FM. Calsenilin reverses presenilin-mediated enhancement of calcium signaling. Proceedings of the National Academy of Sciences of the United States of America. 97: 8590-3. PMID 10900016 DOI: 10.1073/Pnas.97.15.8590 |
0.743 |
|
2000 |
Leissring MA, Akbari Y, Fanger CM, Cahalan MD, Mattson MP, LaFerla FM. Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice. The Journal of Cell Biology. 149: 793-8. PMID 10811821 DOI: 10.1083/Jcb.149.4.793 |
0.725 |
|
2000 |
Mattson MP, LaFerla FM, Chan SL, Leissring MA, Shepel PN, Geiger JD. Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends in Neurosciences. 23: 222-9. PMID 10782128 DOI: 10.1016/S0166-2236(00)01548-4 |
0.541 |
|
1999 |
Leissring MA, Parker I, LaFerla FM. Presenilin-2 mutations modulate amplitude and kinetics of inositol 1, 4,5-trisphosphate-mediated calcium signals. The Journal of Biological Chemistry. 274: 32535-8. PMID 10551803 DOI: 10.1074/Jbc.274.46.32535 |
0.607 |
|
1999 |
Leissring MA, Paul BA, Parker I, Cotman CW, LaFerla FM. Alzheimer's presenilin-1 mutation potentiates inositol 1,4,5-trisphosphate-mediated calcium signaling in Xenopus oocytes. Journal of Neurochemistry. 72: 1061-8. PMID 10037477 DOI: 10.1046/J.1471-4159.1999.0721061.X |
0.598 |
|
1998 |
Leissring MA, Sugarman MC, LaFerla FM. Herpes simplex virus infections and Alzheimer's disease. Implications for drug treatment and immunotherapy. Drugs & Aging. 13: 193-8. PMID 9789723 DOI: 10.2165/00002512-199813030-00002 |
0.468 |
|
1997 |
Weber LL, Leissring MA, Yang AJ, Glabe CG, Cribbs DH, LaFerla FM. Presenilin-1 immunoreactivity is localized intracellularly in Alzheimer's disease brain, but not detected in amyloid plaques. Experimental Neurology. 143: 37-44. PMID 9000444 DOI: 10.1006/Exnr.1996.6348 |
0.531 |
|
Low-probability matches (unlikely to be authored by this person) |
2003 |
Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 40: 1087-93. PMID 14687544 DOI: 10.1016/S0896-6273(03)00787-6 |
0.299 |
|
2006 |
Leissring MA. Proteolytic degradation of the amyloid beta-protein: the forgotten side of Alzheimer's disease. Current Alzheimer Research. 3: 431-5. PMID 17168642 DOI: 10.2174/156720506779025206 |
0.298 |
|
2009 |
Delledonne A, Kouri N, Reinstatler L, Sahara T, Li L, Zhao J, Dickson DW, Ertekin-Taner N, Leissring MA. Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme. Molecular Neurodegeneration. 4: 39. PMID 19835587 DOI: 10.1186/1750-1326-4-39 |
0.293 |
|
2014 |
Maianti JP, McFedries A, Foda ZH, Kleiner RE, Du XQ, Leissring MA, Tang WJ, Charron MJ, Seeliger MA, Saghatelian A, Liu DR. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature. 511: 94-8. PMID 24847884 DOI: 10.1038/Nature13297 |
0.292 |
|
2011 |
Abdul-Hay S, Leissring M, Sahara T, McBride M, Kang D. O1-05-06: Functional cDNA screening identifies BACE-2 as a principal beta-amyloid degrading protease Alzheimer's & Dementia. 7: S105-S105. DOI: 10.1016/J.Jalz.2011.05.261 |
0.292 |
|
2010 |
Ahmed Z, Sheng H, Xu YF, Lin WL, Innes AE, Gass J, Yu X, Wuertzer CA, Hou H, Chiba S, Yamanouchi K, Leissring M, Petrucelli L, Nishihara M, Hutton ML, et al. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. The American Journal of Pathology. 177: 311-24. PMID 20522652 DOI: 10.2353/Ajpath.2010.090915 |
0.29 |
|
2015 |
Abdul-Hay SO, Bannister TD, Wang H, Cameron MD, Caulfield TR, Masson A, Bertrand J, Howard EA, McGuire MP, Crisafulli U, Rosenberry TR, Topper CL, Thompson CR, Schürer SC, Madoux F, ... ... Leissring MA, et al. Selective targeting of extracellular insulin-degrading enzyme by quasi-irreversible thiol-modifying inhibitors. Acs Chemical Biology. PMID 26398879 DOI: 10.1021/Acschembio.5B00334 |
0.289 |
|
2011 |
Leissring M. P2-472: Identification of secretase-independent beta-amyloid-lowering agents via ultra-high throughput compound screening Alzheimer's & Dementia. 7: S464-S464. DOI: 10.1016/J.Jalz.2011.05.1344 |
0.284 |
|
2018 |
Suire CN, Nainar S, Fazio M, Kreutzer AG, Paymozd-Yazdi T, Topper CL, Thompson CR, Leissring MA. Peptidic inhibitors of insulin-degrading enzyme with potential for dermatological applications discovered via phage display. Plos One. 13: e0193101. PMID 29447281 DOI: 10.1371/Journal.Pone.0193101 |
0.283 |
|
2011 |
Abdul-Hay SO, Kang D, McBride M, Li L, Zhao J, Leissring MA. Deletion of insulin-degrading enzyme elicits antipodal, age-dependent effects on glucose and insulin tolerance. Plos One. 6: e20818. PMID 21695259 DOI: 10.1371/Journal.Pone.0020818 |
0.282 |
|
2008 |
Llovera RE, de Tullio M, Alonso LG, Leissring MA, Kaufman SB, Roher AE, de Prat Gay G, Morelli L, Castaño EM. The catalytic domain of insulin-degrading enzyme forms a denaturant-resistant complex with amyloid beta peptide: implications for Alzheimer disease pathogenesis. The Journal of Biological Chemistry. 283: 17039-48. PMID 18411275 DOI: 10.1074/jbc.M706316200 |
0.275 |
|
2009 |
Burgess J, Leissring MA, Ma L, Younkin LH, Reinstatler L, Crook JE, Pankratz VS, Dickson DW, Peterson RC, Graff-Radford NR, Younkin SG, Ertekin-Taner N. P4-128: Association of a missense cathepsin D (CTSD) SNP with risk of Alzheimer's disease Alzheimer's & Dementia. 5: P469-P469. DOI: 10.1016/J.Jalz.2009.04.796 |
0.273 |
|
2004 |
Leissring M, Farris W, Wu X, Selkoe DJ. P4-189 Identification of a novel translational isoform of insulin-degrading enzyme Neurobiology of Aging. 25: S529. DOI: 10.1016/S0197-4580(04)81747-0 |
0.269 |
|
2021 |
Suire CN, Leissring MA. Cathepsin D: A Candidate Link between Amyloid β-protein and Tauopathy in Alzheimer Disease. Journal of Experimental Neurology. 2: 10-15. PMID 33665647 |
0.268 |
|
2010 |
Ahmed Z, Sheng H, Xu YF, Lin WL, Innes AE, Gass J, Yu X, Wuertzer CA, Hou H, Chiba S, Yamanouchi K, Leissring M, Petrucelli L, Nishihara M, Hutton ML, et al. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging (American Journal of Pathology (2010), 177, (311-324)) American Journal of Pathology. 177: 2146. DOI: 10.2353/Ajpath.2010.100772 |
0.265 |
|
2020 |
Merino B, Fernández-Díaz CM, Parrado-Fernández C, González-Casimiro CM, Postigo-Casado T, Lobatón CD, Leissring MA, Cózar-Castellano I, Perdomo G. Hepatic insulin-degrading enzyme regulates glucose and insulin homeostasis in diet-induced obese mice. Metabolism: Clinical and Experimental. 154352. PMID 32916153 DOI: 10.1016/J.Metabol.2020.154352 |
0.264 |
|
2007 |
Farris W, Schütz SG, Cirrito JR, Shankar GM, Sun X, George A, Leissring MA, Walsh DM, Qiu WQ, Holtzman DM, Selkoe DJ. Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. The American Journal of Pathology. 171: 241-51. PMID 17591969 DOI: 10.2353/Ajpath.2007.070105 |
0.26 |
|
2018 |
Villa-Pérez P, Merino B, Fernández-Díaz CM, Cidad P, Lobatón CD, Moreno A, Muturi HT, Ghadieh HE, Najjar SM, Leissring MA, Cózar-Castellano I, Perdomo G. Liver-specific ablation of insulin-degrading enzyme causes hepatic insulin resistance and glucose intolerance, without affecting insulin clearance in mice. Metabolism: Clinical and Experimental. PMID 30098324 DOI: 10.1016/J.Metabol.2018.08.001 |
0.255 |
|
2016 |
Leissring MA. Aβ-Degrading Proteases: Therapeutic Potential in Alzheimer Disease. Cns Drugs. PMID 27349988 DOI: 10.1007/s40263-016-0364-1 |
0.253 |
|
2009 |
Shankar GM, Leissring MA, Adame A, Sun X, Spooner E, Masliah E, Selkoe DJ, Lemere CA, Walsh DM. Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiology of Disease. 36: 293-302. PMID 19660551 DOI: 10.1016/J.Nbd.2009.07.021 |
0.248 |
|
2003 |
Leissring MA, Lu A, Condron MM, Teplow DB, Stein RL, Farris W, Selkoe DJ. Kinetics of amyloid beta-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays. The Journal of Biological Chemistry. 278: 37314-20. PMID 12867419 DOI: 10.1074/Jbc.M305627200 |
0.245 |
|
2014 |
Kurklinsky S, Abdul-Hay SO, McGuire MP, Howard EA, Knight J, Leissring MA. The blood glucose-lowering effect of racecadotril is not attributable to inhibition of insulin-degrading enzyme. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Mã©Tabolisme. 46: 73-4. PMID 23975847 DOI: 10.1055/S-0033-1353211 |
0.244 |
|
2010 |
Miles RJ, DelleDonne A, Zou F, Murray M, Ma L, Nguyen T, Bisceglio G, Dickson DW, Younkin S, Leissring MA, Ertekin-Taner N. P1-095: Characterization of brain region- and disease-specific IDE expression in Alzheimer patients and controls Alzheimer's & Dementia. 6: S202-S202. DOI: 10.1016/J.Jalz.2010.05.643 |
0.235 |
|
2012 |
Saido T, Leissring MA. Proteolytic degradation of amyloid β-protein. Cold Spring Harbor Perspectives in Medicine. 2: a006379. PMID 22675659 DOI: 10.1101/cshperspect.a006379 |
0.231 |
|
2007 |
Leissring M, Saido TC. Aβ degradation Alzheimer's Disease: Advances in Genetics, Molecular and Cellular Biology. 157-178. DOI: 10.1007/978-0-387-35135-3_10 |
0.214 |
|
2003 |
Whitaker C, Eckman C, Almeida C, Feinstein D, Atwood C, Eckman E, Crutcher K, Hersh L, Leissring M, LaVoie M, Ertekin-Taner N, Shapiro P, Takahashi R, Yamin R, Mansourian S, et al. Live discussion: Amyloid-β degradation: The forgotten half of Alzheimer's disease Journal of Alzheimer's Disease. 5: 491-497. PMID 14765518 |
0.207 |
|
2004 |
Leissring MA, Farris W, Wu X, Christodoulou DC, Haigis MC, Guarente L, Selkoe DJ. Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. The Biochemical Journal. 383: 439-46. PMID 15285718 DOI: 10.1042/Bj20041081 |
0.205 |
|
2021 |
González-Casimiro CM, Cámara-Torres P, Merino B, Diez-Hermano S, Postigo-Casado T, Leissring MA, Cózar-Castellano I, Perdomo G. Effects of Fasting and Feeding on Transcriptional and Posttranscriptional Regulation of Insulin-Degrading Enzyme in Mice. Cells. 10. PMID 34572095 DOI: 10.3390/cells10092446 |
0.17 |
|
2021 |
Adamek RN, Suire CN, Stokes RW, Brizuela MK, Cohen SM, Leissring MA. Hydroxypyridinethione Inhibitors of Human Insulin-Degrading Enzyme. Chemmedchem. PMID 33686743 DOI: 10.1002/cmdc.202100111 |
0.167 |
|
2020 |
Suire CN, Brizuela MK, Leissring MA. Quantitative, High-Throughput Assays for Proteolytic Degradation of Amylin. Methods and Protocols. 3. PMID 33255272 DOI: 10.3390/mps3040081 |
0.161 |
|
2006 |
Leissring MA, Selkoe DJ. Structural biology: enzyme target to latch on to. Nature. 443: 761-2. PMID 17051198 DOI: 10.1038/nature05210 |
0.157 |
|
2021 |
González-Casimiro CM, Merino B, Casanueva-Álvarez E, Postigo-Casado T, Cámara-Torres P, Fernández-Díaz CM, Leissring MA, Cózar-Castellano I, Perdomo G. Modulation of Insulin Sensitivity by Insulin-Degrading Enzyme. Biomedicines. 9. PMID 33477364 DOI: 10.3390/biomedicines9010086 |
0.156 |
|
2022 |
Merino B, Casanueva-Álvarez E, Quesada I, González-Casimiro CM, Fernández-Díaz CM, Postigo-Casado T, Leissring MA, Kaestner KH, Perdomo G, Cózar-Castellano I. Insulin-degrading enzyme ablation in mouse pancreatic alpha cells triggers cell proliferation, hyperplasia and glucagon secretion dysregulation. Diabetologia. PMID 35652923 DOI: 10.1007/s00125-022-05729-y |
0.141 |
|
2023 |
Merino B, Casanueva-Álvarez E, Quesada I, González-Casimiro CM, Fernández-Díaz CM, Postigo-Casado T, Leissring MA, Kaestner KH, Perdomo G, Cózar-Castellano I. Correction to: Insulin-degrading enzyme ablation in mouse pancreatic alpha cells triggers cell proliferation, hyperplasia and glucagon secretion dysregulation. Diabetologia. PMID 37966551 DOI: 10.1007/s00125-023-06037-9 |
0.132 |
|
2021 |
Leissring MA, González-Casimiro CM, Merino B, Suire CN, Perdomo G. Targeting Insulin-Degrading Enzyme in Insulin Clearance. International Journal of Molecular Sciences. 22. PMID 33668109 DOI: 10.3390/ijms22052235 |
0.122 |
|
2018 |
Suire CN, Lane S, Leissring MA. Development and Characterization of Quantitative, High-Throughput-Compatible Assays for Proteolytic Degradation of Glucagon. Slas Discovery : Advancing Life Sciences R & D. 2472555218786509. PMID 29995452 DOI: 10.1177/2472555218786509 |
0.114 |
|
2021 |
Leissring MA. Insulin-Degrading Enzyme: Paradoxes and Possibilities. Cells. 10. PMID 34572094 DOI: 10.3390/cells10092445 |
0.107 |
|
Hide low-probability matches. |